logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics' Cath O'Neill 'thrilled' with human study data for skin cream

Dr Cath O’Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), speaks to Proactive's Andrew Scott after announcing the results from the company’s first human study of its SkinBiotix cream.

The data has shown the product to be well tolerated and efficacious in certain age groups and at certain time points.

Quick facts: SkinBioTherapeutics PLC

Price: - -

AIM:SBTX
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics inks commercial deal with FTSE 100 chemical firm Croda

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive London's Andrew Scott after announcing they've inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA). Ashman says it's a significant first...

on 20/11/19

2 min read